Key Takeaways
- Shares of Viking Therapeutics rallied more than 39% during pre-market hours following positive top-line data from the VK2735 maintenance trial
- The 17.5mg weekly dosage of VK2735 delivered 22% placebo-adjusted weight reduction over a 33-week period
- During maintenance testing, bi-weekly administration maintained up to 97% of weight loss, while monthly dosing preserved up to 90%, compared to just 61% retention in the placebo cohort
- Safety data revealed a positive tolerability profile, with gastrointestinal side effects matching placebo levels
- The biotech company reported $502 million in cash reserves at the close of Q2, while Oppenheimer analysts held firm on their $100 target price before the data release
Viking Therapeutics shares skyrocketed more than 39% in Tuesday’s pre-market session, reaching $42 per share and nearing the 52-week peak of $43.15. The dramatic price movement followed the company’s announcement of top-line data from its maintenance study evaluating VK2735, an injectable dual agonist targeting both GLP-1 and GIP receptors.
Viking Therapeutics, Inc., VKTX
The data originated from the VK2735-102 clinical trial, structured in two distinct phases. During the initial 21-week induction phase, participants receiving once-weekly VK2735 treatment experienced weight reductions ranging from approximately 16% to 19%, while placebo recipients saw essentially no weight change.
The maintenance phase data proved particularly compelling for investors. Over the subsequent 12-week maintenance period, participants transitioning to bi-weekly administration maintained as much as 97% of their previously achieved weight loss. Those shifting to once-monthly dosing preserved up to 90% of their results. By contrast, the placebo cohort retained only 61% of their weight loss.
Participants on the 17.5mg weekly regimen achieved a placebo-adjusted weight loss of 22% when measured across the complete 33-week study duration.
Favorable Safety Data Emerges
The drug’s tolerability profile emerged as another significant positive from the trial. Gastrointestinal adverse events during the maintenance phase occurred at rates similar to those observed in the placebo group.
Discontinuation rates remained low throughout the study. A single patient withdrew during the induction phase due to adverse effects. One participant each from the bi-weekly and monthly dosing cohorts discontinued during the maintenance phase.
This favorable tolerability profile carries particular significance in a therapeutic category where gastrointestinal side effects have presented ongoing challenges for competing medications.
Ahead of the data release, Oppenheimer analysts maintained their Outperform rating with a $100 price target. The firm had suggested many market participants assumed Eli Lilly’s tirzepatide would control the GLP-1/GIP market, and that positive VK2735 maintenance results could reframe competitive dynamics around dosing flexibility and patient compliance.
Future Development Plans
Viking intends to investigate oral maintenance dosing protocols for VK2735 through a Part 2 segment of the ongoing trial, expanding beyond the subcutaneous injection formulation evaluated in this study.
The company had previously communicated expectations for maintenance data availability in Q3 2026. That timeline remains unchanged.
As of the end of Q2 2026, Viking maintained cash reserves of $502 million, providing adequate capital to advance its development pipeline through subsequent clinical stages.
The broader equity markets showed minimal movement on Tuesday, indicating the stock surge was entirely driven by company-specific news. The S&P 500 edged up 0.1%, the Nasdaq gained 0.05%, and the Dow Jones added 0.3%.
Having previously touched a 52-week high of $43.15, the stock’s pre-market price of $42 represents a near-return to that peak level.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
